Intranasal drug delivery: opportunities and toxicologic challenges during drug development

被引:306
|
作者
Keller, Lea-Adriana [1 ,2 ]
Merkel, Olivia [2 ]
Popp, Andreas [1 ]
机构
[1] AbbVie Deutschland GmbH & Co KG, Preclin Safety, Knollstr, D-67061 Ludwigshafen, Germany
[2] Ludwig Maximilians Univ Munchen, Dept Pharm Pharmaceut Technol & Biopharm, Butenandtstr 5-13, D-81337 Munich, Germany
关键词
Intranasal drug delivery; Olfactory pathways; Nose-to-brain-delivery; Nasal toxicity; NASAL MUCOCILIARY CLEARANCE; GERM AGGLUTININ-HORSERADISH; CILIARY BEAT FREQUENCY; CENTRAL-NERVOUS-SYSTEM; RAT OLFACTORY SYSTEM; BLOOD-BRAIN-BARRIER; ALZHEIMERS-DISEASE; STEM-CELLS; BENZALKONIUM CHLORIDE; RESPIRATORY MUCOSA;
D O I
10.1007/s13346-020-00891-5
中图分类号
TH7 [仪器、仪表];
学科分类号
0804 ; 080401 ; 081102 ;
摘要
Over the past 10 years, the interest in intranasal drug delivery in pharmaceutical R&D has increased. This review article summarises information on intranasal administration for local and systemic delivery, as well as for CNS indications. Nasal delivery offers many advantages over standard systemic delivery systems, such as its non-invasive character, a fast onset of action and in many cases reduced side effects due to a more targeted delivery. There are still formulation limitations and toxicological aspects to be optimised. Intranasal drug delivery in the field of drug development is an interesting delivery route for the treatment of neurological disorders. Systemic approaches often fail to efficiently supply the CNS with drugs. This review paper describes the anatomical, histological and physiological basis and summarises currently approved drugs for administration via intranasal delivery. Further, the review focuses on toxicological considerations of intranasally applied compounds and discusses formulation aspects that need to be considered for drug development.
引用
收藏
页码:735 / 757
页数:23
相关论文
共 50 条
  • [41] Challenges and opportunities in childhood cancer drug development
    Robin E. Norris
    Peter C. Adamson
    Nature Reviews Cancer, 2012, 12 : 776 - 782
  • [42] Opportunities and Challenges in Drug Development for Pediatric Cancers
    Laetsch, Theodore W.
    DuBois, Steven G.
    Bender, Julia Glade
    Macy, Margaret E.
    Moreno, Lucas
    CANCER DISCOVERY, 2021, 11 (03) : 545 - 559
  • [43] Drug discovery and development for ageing: opportunities and challenges
    Evans, William J.
    PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES, 2011, 366 (1561) : 113 - 119
  • [44] Challenges and Opportunities in Rare Disease Drug Development
    Smith, B. P.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2016, 100 (04) : 312 - 314
  • [45] Challenges and opportunities in childhood cancer drug development
    Norris, Robin E.
    Adamson, Peter C.
    NATURE REVIEWS CANCER, 2012, 12 (11) : 776 - 782
  • [46] OPPORTUNITIES AND CHALLENGES IN DRUG DEVELOPMENT FOR RETINAL DISEASES
    Jakubiak, Paulina
    DRUG METABOLISM AND PHARMACOKINETICS, 2024, 55
  • [47] Challenges and opportunities in drug development for nonalcoholic steatohepatitis
    Ocker, Matthias
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2020, 870
  • [48] Opportunities and Challenges in the Anticandidal Drug Discovery and Development
    Abid, Mohammad
    LETTERS IN DRUG DESIGN & DISCOVERY, 2019, 16 (05) : 477 - 477
  • [49] Challenges and Opportunities With Oncology Drug Development in China
    Bajaj, Gaurav
    Gupta, Manish
    Wang, Hwei-Gene Heidi
    Barrett, Jeffrey S.
    Tan, Matthew
    Rupalla, Katrin
    Bertz, Richard
    Sheng, Jennifer
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2019, 105 (02) : 363 - 375
  • [50] A snapshot of biologic drug development: Challenges and opportunities
    Andrews, L.
    Ralston, S.
    Blomme, E.
    Barnhart, K.
    HUMAN & EXPERIMENTAL TOXICOLOGY, 2015, 34 (12) : 1279 - 1285